Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) Director George M. Jenkins purchased 4,000 shares of Palvella Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was acquired at an average price of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the acquisition, the director now owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Palvella Therapeutics Stock Up 1.8 %
NASDAQ PVLA opened at $12.00 on Friday. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $22.32.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald began coverage on Palvella Therapeutics in a research report on Wednesday. They issued an “overweight” rating on the stock.
Featured Articles
- Five stocks we like better than Palvella Therapeutics
- ETF Screener: Uses and Step-by-Step Guide
- Why Wall Street Sees Major Upside for PayPal Stock
- Most Volatile Stocks, What Investors Need to Know
- Cintas Shares Slide: A Prime Opportunity to Buy the Dip
- Insider Buying Explained: What Investors Need to Know
- Tempus AI: A Potential Double-Bagger After Recent Pullback
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
